On genotype-phenotype relationship  of dystrophinopathies among Iranian population

Keivan Basiri; Maryam Alizadeh; Behnaz Ansari; Majid Ghasemi; Mohsen Kheradmand; Maryam Sedghi

doi:10.18502/cjn.v22i4.14528

Keivan Basiri Isfahan Neuroscience Research Center, Al-Zahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Maryam Alizadeh Department of Neurology, School of Medicine, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Behnaz Ansari Isfahan Neuroscience Research Center, Al-Zahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Majid Ghasemi Isfahan Neuroscience Research Center, Al-Zahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Mohsen Kheradmand Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Maryam Sedghi Medical Genetics Laboratory, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

DOI: https://doi.org/10.18502/cjn.v22i4.14528

Keywords: Duchenne Muscular Dystrophy; Phenotype; Genotype; Dystrophin; Iran

Abstract

Background: Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are inherited
X-linked disorders resulting from alterations in the dystrophin gene. Genotype-phenotype matching studies have revealed a link between disease severity, the amount of muscle dystrophin, and the extent of mutation/deletion on the dystrophin gene. This study aimed to assess the relationship between genetic alterations in the dystrophin gene and the clinical status of patients with dystrophinopathies among the Iranian population.

Methods: This cross-sectional study examined 54 patients with muscle weakness caused by abnormalities in the dystrophin gene at a hospital affiliated to Isfahan University of Medical Sciences, Isfahan, Iran, in 2021. The participants’ demographic information, including age, family history of muscle dystrophies, and family history of other medical diseases as well as the type of muscular dystrophy were recorded. Furthermore, the number and region of deleted exons based on dystrophy types were also evaluated using multiplex ligation-dependent probe amplification (MLPA). The patients’ gaits were also assessed as using a wheelchair, the presence of waddling gaits, or toe gaits. The patients’ clinical status and the coexistence of pulmonary, bulbar, and mental conditions were also examined and compared between the two groups of dystrophinopathies.

Results: In this study, 54 patients with dystrophinopathy with the mean age of 16.63 ± 12.10 years were evaluated, of whom 22 (40.7%) and 30 (55.6%) patients were classified as BMD and DMD, respectively. The most affected regions with deleted exons were exons 45-47 (n = 5) and 45-48 (n = 4) in patients with BMD, while exons 45, 48-52, 51-55, and 53 (2 cases per exon) were the most common affected exons in patients with DMD. Further analyses revealed that deletions in exons 45-47 and 51-55 were significantly associated with older and younger ages at the onset of becoming wheelchair-bound in patients with dystrophy, respectively. The hotspot range in both BMD and DMD was within exons 45-55 (n = 15 for each group); 63% of the patients had alterations on the dystrophin gene within this range [30 patients (68.18%) in the BMD group, 15 patients (53.57%) in the DMD group].

Conclusion: Exon deletion was the most common genetic alteration in patients with dystrophinopathies. No significant difference was observed between DMD and BMD regarding the number of deleted exons. Deletions in exons 45-47 and 51-55 were linked to later and earlier onset of becoming wheelchair-bound, respectively.